Abstracts tagged "Patient reported outcomes"

Abstract Number: 0412 • ACR Convergence 2022
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Lianne Gensler³, Jonathan Kay⁴, Victoria Navarro-Compán⁵, Christine de la Loge⁶, Alicia Ellis⁷, Carmen Fleurinck⁸, Marga Oortgiesen⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Colombes, France, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impacts patients' (pts) physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively…
Abstract Number: 0838 • ACR Convergence 2022
Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
Lisa Mandl¹, Benjamin Swett¹, Robyn Lipschultz¹, Myriam Lin¹, Alison Zhao², Carola Hanreich¹, Dongmei Sun¹, Kethy Jules-elysee¹ and Friedrich Boettner¹, ¹Hospital for Special Surgery, New York, NY, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Background/Purpose: Over 520 million people have been infected by SARS-CoV-2. In 10-40%, disabling symptoms such as fatigue and dyspnea can persist. Risk factors for poor…
Abstract Number: 1272 • ACR Convergence 2022
Application of the Consolidated Framework for Implementation Research (CFIR) to Study Top-Performing Practices in the RISE Registry
Lindsay Jacobsohn¹, Catherine Nasrallah², Cammie Young³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Collection and use of rheumatoid arthritis (RA) disease activity and functional status outcome measures facilitates treating-to-target and shared decision-making. Although guidelines recommend regular use…
Abstract Number: 1392 • ACR Convergence 2022
Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
Maria Mirza¹, Kaiyang Song¹, Madiha Ashraf², Anushka Soni³, John Jackman³ and Raashid Luqmani¹, ¹Oxford University Hospital, Oxford, United Kingdom, ²Oxford Universtiy Hospital, Oxford, United Kingdom, ³Oxford University Hospital, Oxford, England, United Kingdom
Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…
Abstract Number: 1927 • ACR Convergence 2022
Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults
Rebecca Overbury¹, Devin Eddington², Katherine Sward², John Bohnsack¹, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City
Background/Purpose: The Adult Center for Childhood Onset Rheumatic Disease (ACCORD) is a clinical and research center for the health care transition (HCT) of adolescent and…
Abstract Number: 2170 • ACR Convergence 2022
Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
Francesco Del Galdo¹, Suiyuan Huang², Lesley-Anne Bissell³, sindhu johnson⁴, Daniel Furst⁵ and Dinesh Khanna⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ²University of Michigan, Ann Arbor, MI, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
Abstract Number: 0155 • ACR Convergence 2022
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Sarvar Nazir¹, Kelly Rouster-Stevens², Julie Fuller³, Hanna Kim⁴, Vy Do⁵, Rita Volochayev⁶, Anna Jansen⁶, Nastaran Bayat⁷, Lisa G Rider⁸ and Adam Schiffenbauer⁶, ¹National Institutes of Health, Charlotte, NC, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³UT Southwestern, Frisco, TX, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁵UT Austin Dell Medical School, Austin, TX, ⁶National Institutes of Health, Bethesda, MD, ⁷Social & Scientific Systems, Inc., a DLH Holdings Corp (DLH) company, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…
Abstract Number: 0269 • ACR Convergence 2022
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
Marijke van den Dikkenberg¹, Martijn Kuijper², Marc Kok¹, Deirisa Lopes Barreto² and Angelique Weel¹, ¹Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam
Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
Abstract Number: 0428 • ACR Convergence 2022
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
Devika dua and Tim Blake, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
Background/Purpose: To determine if there is a significant variation in biologic usage in axSpa patients and to identify factors associated with it.Methods: We collected retrospective…
Abstract Number: 0843 • ACR Convergence 2022
Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021
Troy B Amen¹, Yi Zhang,¹, John Gibbons¹, Orett Burke¹, Anne Bass², Linda Russell¹, huong do¹, Ying Lai¹, Michael Parks¹, Mark Figgie¹, Bella Mehta³ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Racial and ethnic disparities in total joint arthroplasty utilization have been extensively reported, demonstrating significantly lower rates of utilization among Black and Hispanic patients;…
Abstract Number: 1298 • ACR Convergence 2022
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Catherine Bingham¹, Julia Harris², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Kerry Ferraro⁶, Tingting Qiu⁷, Jon Burnham⁸, Michelle Batthish⁹, Beth Gottlieb¹⁰, Daniel Lovell⁷, Ronald Laxer¹¹, Tzielan Lee¹², Danielle Bullock¹³, Charles H Spencer¹⁴, Jennifer Weiss¹⁵, Melissa Hazen¹⁶, Edward Oberle¹⁷, Melissa Mannion¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Danielle Fair²¹, Mary Toth²², Kendra Wiegand⁷ and Esi Morgan²³, ¹Penn State Children's Hospital, Hershey, PA, ²Children's Mercy Kansas City, Overland Park, KS, ³Atrium Health Levine Children's, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Texas Children's Hospital/ Baylor College of Medicine, Houston, TX, ⁶Pediatric Rheumatology Care and Outcomes Improvement Network, Philadelphia, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁵Hackensack University Medical Center, Hackensack, NJ, ¹⁶Boston Children's Hospital, Boston, MA, ¹⁷Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ²²Nemours Foundation, Orlando, FL, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic…
Abstract Number: 1409 • ACR Convergence 2022
Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
Guillermo Guaracha Basañez¹, Irazu Contreras-Yáñez², Vivian Estrada-González², Lexli Pacheco-Santiago², Salvador Valverde-Hernández² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Patients and physicians can naturally adopt hybrid healthcare models (HC), that combine face-to-face consultations (FFC) with telemedicine. The study's objective was to compare the…
Abstract Number: 1952 • ACR Convergence 2022
Burden of Disease in Refractory Rheumatoid Arthritis
Kristin Wipfler¹, Bobby Kwanghoon Han², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Iris Lin⁶, Patricia Katz⁷, Evo Alemao⁸ and Kaleb Michaud⁹, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Johnson & Johnson, Beerse, Belgium, ⁴Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁵Janssen Research and Development, Chapel Hill, NC, ⁶Janssen, Horsham, PA, ⁷UCSF, San Rafael, CA, ⁸Janssen, Princeton, NJ, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…
Abstract Number: 2174 • ACR Convergence 2022
Influence of Immunosuppressive Therapy on Gastrointestinal Symptoms in Patients with Systemic Sclerosis
Lea Stamm¹, Alexandru Garaiman¹, Norina Zampatti¹, Mike Becker¹, Cosimo Bruni¹, Rucsandra Dobrota¹, Muriel Elhai¹, Sherif Ismail², Suzana Jordan¹, Aurora Tatu³, Oliver Distler¹ and Carina Mihai¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Internal Medicine, National Research Center, Cairo, Egypt, ³Department of Gastroenterology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: The gastrointestinal (GI) tract is frequently affected in systemic sclerosis (SSc), leading to considerable morbidity and even mortality. While important progress has been made…
Abstract Number: 0184 • ACR Convergence 2022
Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
Daniel Hernandez¹, Julio Bravo², Juan Maya Villamizar³, William Benjamin Nowell¹, Oscar Soto-Raices⁴, Angel Tapia⁵, Guillermo Valenzuela⁶ and Shilpa Venkatachalam⁷, ¹Global Healthy Living Foundation, Nyack, NY, ²Novant, Winston-Salem, NC, ³Rheumatology Center of Palm Beach, PLLC, Boca Raton, FL, ⁴Fundación FER, San Juan, PR, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁷Global Healthy Living Foundation, New York, NY
Background/Purpose: There is little research on rheumatoid arthritis (RA) in the US Hispanic population (< 0.2% of publications on RA indexed in PubMed.gov), but it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.